Good question. Although it could be argued that the recent...

Good question. Although it could be argued that the recent thrust has a lot to do with how undervalued PAR was post the successful trial.

If there wasn't more potential news on the horizon then I'd definitely be looking for significant consolidation / correction to kick in. But it may take a bit of courage to walk away with as much potential news due in Q1/Q2 2019 such as....

- Secondary end-point data (normally a bit ho hum - but in this case could provide strong evidence around the unique MOA of PPS given we will (hopefully) see the MRI results - a pure objective parameter that won't be subject to potential misinterpretation by the market)
- MPS SAS - bearing in mind there could be a business built just around this indication
- ex-NFL players - will raise news in the US - although I wonder how much interest there will be from American traders

And there is a lot more to come too. The filing of the IND in Q3 CY2019 would be worthwhile waiting for alone.

I'm pleased I didn't walk away mid-January - but am struggling to see why I'd walk away just yet - and particularly as there seems to best much potential upside around news

Lots more to come